Your browser is no longer supported. Please, upgrade your browser.
Settings
KPTI Karyopharm Therapeutics Inc. daily Stock Chart
KPTI [NASD]
Karyopharm Therapeutics Inc.
Index- P/E- EPS (ttm)-3.55 Insider Own0.10% Shs Outstand59.39M Perf Week22.29%
Market Cap703.77M Forward P/E- EPS next Y-2.50 Insider Trans0.00% Shs Float50.64M Perf Month34.66%
Income-215.90M PEG- EPS next Q-0.84 Inst Own93.60% Short Float22.39% Perf Quarter97.83%
Sales10.10M P/S69.68 EPS this Y-11.80% Inst Trans-0.02% Short Ratio4.47 Perf Half Y123.16%
Book/sh1.35 P/B8.78 EPS next Y27.50% ROA-79.50% Target Price19.89 Perf Year-37.17%
Cash/sh3.66 P/C3.24 EPS next 5Y- ROE-154.70% 52W Range3.92 - 19.37 Perf YTD26.47%
Dividend- P/FCF- EPS past 5Y10.90% ROI-62.90% 52W High-38.82% Beta2.44
Dividend %- Quick Ratio6.90 Sales past 5Y139.20% Gross Margin- 52W Low202.30% ATR0.63
Employees332 Current Ratio6.90 Sales Q/Q-52.30% Oper. Margin- RSI (14)78.77 Volatility7.32% 6.24%
OptionableYes Debt/Eq1.29 EPS Q/Q-18.80% Profit Margin- Rel Volume1.55 Prev Close11.03
ShortableYes LT Debt/Eq1.29 EarningsAug 06 BMO Payout- Avg Volume2.53M Price11.85
Recom1.40 SMA2026.95% SMA5034.47% SMA20061.00% Volume3,936,409 Change7.43%
Jul-23-19Upgrade JP Morgan Neutral → Overweight $8 → $16
Jul-05-19Reiterated Robert W. Baird Outperform $15 → $25
Jul-05-19Reiterated H.C. Wainwright Buy $29 → $32
Mar-01-19Downgrade JP Morgan Overweight → Neutral $21 → $7
Feb-28-19Reiterated BofA/Merrill Underperform $15 → $5
Feb-27-19Downgrade BofA/Merrill Neutral → Underperform $15 → $5
Jan-03-19Upgrade BofA/Merrill Underperform → Neutral
Dec-03-18Initiated B. Riley FBR Buy $23
Nov-09-18Upgrade Wedbush Neutral → Outperform $19
May-24-18Downgrade Wedbush Outperform → Neutral $20 → $19
Apr-02-18Resumed Leerink Partners Outperform $19
Nov-15-17Resumed H.C. Wainwright Buy $23
Sep-15-17Initiated RBC Capital Mkts Outperform $14
Sep-08-16Reiterated H.C. Wainwright Buy $15 → $16
Aug-30-16Upgrade Jefferies Hold → Buy
Aug-18-16Initiated H.C. Wainwright Buy $15
Jun-28-16Initiated Robert W. Baird Outperform $16
May-27-16Initiated Raymond James Outperform $13
Mar-16-16Reiterated Wedbush Outperform $38 → $16
Jan-06-16Downgrade Jefferies Buy → Hold
Sep-16-19 10:50PM  SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire +7.43%
02:05PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of KPTI, GVA and NTAP ACCESSWIRE
01:30PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. GlobeNewswire
11:10AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPTI, NGHC and GTT ACCESSWIRE
10:40AM  SHAREHOLDER ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 ACCESSWIRE
10:30AM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. GlobeNewswire
08:50AM  7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
07:00AM  Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million GlobeNewswire
Sep-15-19 11:05AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of OMCL, KPTI and NGHC ACCESSWIRE
Sep-13-19 10:50PM  SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire
06:30PM  Karyopharm Announces XPOVIO (Selinexor) Presentations at the 17th International Myeloma Workshop GlobeNewswire
04:30PM  SHAREHOLDER ALERT: VNTR KPTI MNK: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
03:30PM  Zhang Investor Law Reminds Investors of September 23 Deadline in Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI ACCESSWIRE
03:00PM  Class Action Update - NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
11:00AM  SHAREHOLDER ALERT: KPTI GTT SRPT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
10:22AM  Class Action Alert - NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-12-19 06:40PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPTI, EGBN and MNK ACCESSWIRE
05:05PM  ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action KPTI GlobeNewswire
03:30PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPTI, GVA and IFF ACCESSWIRE
02:44PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI GlobeNewswire
02:30PM  SEPTEMBER DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
09:32AM  SHAREHOLDER ALERT: OMCL KPTI NTAP TXT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
06:10AM  CLASS ACTION LAWSUIT UPDATE: Brodsky & Smith, LLC Is Investigating Securities Violations by the Following Companies: KPTI, IFF, PS ACCESSWIRE
Sep-11-19 10:50PM  SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire
06:05PM  CLASS ACTION UPDATE for NFLX, KPTI and GVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
05:00PM  FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
12:15PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of OMCL, KPTI and GVA ACCESSWIRE
10:21AM  Class Action Update - NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
09:24AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of RBGLY, KPTI, PS and TXT GlobeNewswire
06:35AM  CLASS ACTION UPDATE: Brodsky & Smith, LLC Is Investigating Securities Violations Related to the Following Companies: LB, KPTI and CURLF ACCESSWIRE
Sep-10-19 07:30PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Omnicell, Ideanomics, Eagle Bancorp, and Karyopharm and Encourages Investors to Contact the Firm GlobeNewswire +6.40%
06:15PM  SEPTEMBER 23 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
04:55PM  SHAREHOLDER ALERT: KPTI GTT GVA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
04:30PM  NATIONALLY RANKED ROSEN LAW FIRM Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM KPTI GlobeNewswire
12:35PM  CLASS ACTION UPDATE for LB, KPTI and IFF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
11:01AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc.  To Contact The Firm GlobeNewswire
09:38AM  CLASS ACTION UPDATE for OMCL, KPTI, CURLF and TWOU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
09:30AM  KPTI DEADLINE ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI ACCESSWIRE
Sep-09-19 10:50PM  SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire
07:00PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OMCL, KPTI and VAL ACCESSWIRE
10:45AM  CLASS ACTION UPDATE for VERB, LB and KPTI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:20AM  Class Action Reminder - NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
09:40AM  UPCOMING DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Sep-08-19 10:45AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPTI, EGBN and ABMD ACCESSWIRE
Sep-07-19 02:53PM  SEPTEMBER DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Sep-06-19 10:55PM  Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI ACCESSWIRE
10:50PM  SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire
03:15PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPTI, EGBN and NTAP ACCESSWIRE
01:15PM  FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
12:15PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of OMCL, KPTI and IFF ACCESSWIRE
11:29AM  Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study Zacks
09:49AM  NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC - Class Action ACCESSWIRE
09:27AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of KPTI, EGBN, MNK and CAH GlobeNewswire
06:17AM  CLASS ACTION NOTICE: Brodsky & Smith, LLC Is Investigating Securities Violations ACCESSWIRE
Sep-05-19 05:50PM  MID-SEPTEMBER DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +10.79%
04:05PM  SHAREHOLDER ALERT: RBGLY LB KPTI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
03:44PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI GlobeNewswire
12:20PM  SHAREHOLDER ALERT: VNTR KPTI TWOU: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
10:48AM  NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC - Class Action Reminder ACCESSWIRE
10:10AM  SHAREHOLDER ALERT: INS KPTI EGBN VAL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
08:01AM  Is Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Salary Justified? Simply Wall St.
Sep-04-19 11:00PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm GlobeNewswire
10:50PM  SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire
03:30PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LB, KPTI and MNK ACCESSWIRE
03:00PM  NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC Class Action Update GlobeNewswire
02:45PM  DEADLINE RAPIDLY APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
09:33AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of INS, OMCL, KPTI and CAH GlobeNewswire
06:14AM  CLASS ACTION UPDATE: Brodsky & Smith, LLC Provides Update Regarding Investigation of Securities Violations ACCESSWIRE
Sep-03-19 11:35PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm Newsfile
10:30PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ideanomics, Eagle Bancorp, Karyopharm Therapeutics, and National General Holdings and Encourages Investors to Contact the Firm GlobeNewswire
06:30PM  IMPORTANT SEPTEMBER DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
04:45PM  CLASS ACTION UPDATE for OMCL, KPTI and ABMD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
04:35PM  KPTI LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action - KPTI ACCESSWIRE
04:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI ACCESSWIRE
12:20PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPTI, NGHC and CARB ACCESSWIRE
09:47AM  NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC - Class Action Update ACCESSWIRE
09:46AM  CLASS ACTION UPDATE for NFLX, KPTI, GVA and CVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
08:40AM  UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
07:00AM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-02-19 10:50PM  SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire
Sep-01-19 10:15AM  CLASS ACTION UPDATE for MMM, VERB and KPTI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
Aug-30-19 10:50PM  SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire
03:30PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of VERB, KPTI and CURLF ACCESSWIRE
03:00PM  Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) - Bronstein, Gewirtz & Grossman, LLC Class Action Update GlobeNewswire
10:30AM  CLASS ACTION UPDATE for KPTI, NGHC and MNK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
09:56AM  KPTI, MNK & NGHC - Bronstein, Gewirtz & Grossman, LLC - Class Action Update ACCESSWIRE
Aug-29-19 03:35PM  SHAREHOLDER ALERT: KPTI EGBN PS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
01:29PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI GlobeNewswire
12:56PM  ROSEN, A TOP RANKED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action - KPTI GlobeNewswire
12:45PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of DBD, KPTI and EGBN ACCESSWIRE
11:28AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm GlobeNewswire
09:14AM  SHAREHOLDER ALERT: LB KPTI EVH VAL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Aug-28-19 10:50PM  SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire
03:00PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NFLX, KPTI and VAL ACCESSWIRE
01:00PM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
12:15PM  SHAREHOLDER ALERT: KPTI TWOU VAL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
10:53AM  KPTI, MNK & NGHC - Bronstein, Gewirtz & Grossman, LLC - Class Action ACCESSWIRE
09:14AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPTI, JE, GTT and VAL GlobeNewswire
07:00AM  Karyopharm to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-27-19 09:00PM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Karyopharm Therapeutics Inc., an oncology-focused pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor), which has received approval from the Food and Drug Administration in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma, as well as is under review by the European Medicines Agency. The company also reported positive results from the Phase 2b SADAL study evaluating selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma. Selinexor is also being evaluated in various other mid-and later-phase clinical trials in various cancer indications, including in multiple myeloma in a randomized Phase 3 study in combination with Velcade (bortezomib) and low-dose dexamethasone (BOSTON), as well as a therapy in combination with approved therapies (STOMP), in liposarcoma (SEAL), in recurrent gliomas (KING), in endometrial cancer (SIENDO), and others. The company's SINE compounds also have biological activity in various models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. In addition, it has various investigational programs in clinical or preclinical development. The company was founded in 2008 and is headquartered in Newton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chione Ltd10% OwnerFeb 28Sale4.14149,624619,1146,000,000Mar 04 08:28 PM
Chione Ltd10% OwnerFeb 27Sale4.51558,2432,515,8346,149,624Feb 27 08:12 PM
Chione Ltd10% OwnerFeb 26Sale5.00123,400617,2106,707,867Feb 27 08:12 PM
Chione Ltd10% OwnerFeb 25Sale4.99800,0003,994,8806,831,267Feb 27 08:12 PM
Shacham SharonPresident & CSOJan 07Option Exercise0.0312,500413743,634Jan 09 04:37 PM
Kauffman MichaelChief Executive OfficerJan 07Option Exercise0.0312,500413743,634Jan 09 04:41 PM
Shacham SharonPresident & CSOJan 07Sale10.2312,500127,824731,134Jan 09 04:37 PM
Kauffman MichaelChief Executive OfficerJan 07Sale10.2312,500127,824731,134Jan 09 04:41 PM
Kauffman MichaelChief Executive OfficerDec 07Option Exercise0.0312,500413726,010Dec 10 04:29 PM
Shacham SharonPresident & CSODec 07Option Exercise0.0312,500413726,010Dec 10 04:28 PM
Kauffman MichaelChief Executive OfficerDec 07Sale10.1112,500126,423713,510Dec 10 04:29 PM
Shacham SharonPresident & CSODec 07Sale10.1112,500126,423713,510Dec 10 04:28 PM
Kauffman MichaelChief Executive OfficerNov 26Option Exercise4.759,60045,619521,743Nov 27 04:17 PM
Shacham SharonPresident & CSONov 26Option Exercise4.759,60045,619521,743Nov 27 04:20 PM
Shacham SharonPresident & CSONov 26Sale11.009,600105,600512,143Nov 27 04:20 PM
Kauffman MichaelChief Executive OfficerNov 26Sale11.009,600105,600512,143Nov 27 04:17 PM
Kauffman MichaelChief Executive OfficerNov 19Option Exercise4.754001,901512,543Nov 21 08:00 AM
Shacham SharonPresident & CSONov 19Option Exercise4.754001,901512,543Nov 21 08:03 AM
Shacham SharonPresident & CSONov 19Sale11.144004,455512,143Nov 21 08:03 AM
Kauffman MichaelChief Executive OfficerNov 19Sale11.144004,455512,143Nov 21 08:00 AM
Shacham SharonPresident & CSONov 07Option Exercise0.0312,500413726,010Nov 09 04:16 PM
Kauffman MichaelChief Executive OfficerNov 07Option Exercise0.0312,500413726,010Nov 09 04:17 PM
Shacham SharonPresident & CSONov 07Sale11.6512,500145,593713,510Nov 09 04:16 PM
Kauffman MichaelChief Executive OfficerNov 07Sale11.6512,500145,593713,510Nov 09 04:17 PM
Shacham SharonPresident & CSOOct 18Option Exercise4.7510,00047,520522,143Oct 22 04:09 PM
Kauffman MichaelChief Executive OfficerOct 18Option Exercise4.7510,00047,520522,143Oct 22 04:06 PM
Kauffman MichaelChief Executive OfficerOct 18Sale12.6310,000126,304512,143Oct 22 04:06 PM
Shacham SharonPresident & CSOOct 18Sale12.6310,000126,304512,143Oct 22 04:09 PM
Shacham SharonPresident & CSOOct 08Option Exercise0.0312,500413726,010Oct 09 08:00 AM
Kauffman MichaelChief Executive OfficerOct 08Option Exercise0.0312,500413726,010Oct 09 08:05 AM
Shacham SharonPresident & CSOOct 08Sale15.7512,500196,832713,510Oct 09 08:00 AM
Kauffman MichaelChief Executive OfficerOct 08Sale15.7512,500196,832713,510Oct 09 08:05 AM
Kauffman MichaelChief Executive OfficerSep 18Option Exercise4.7510,00047,520522,143Sep 18 05:23 PM
Shacham SharonPresident & CSOSep 18Option Exercise4.7510,00047,520522,143Sep 18 05:26 PM
Shacham SharonPresident & CSOSep 18Sale18.2610,000182,615512,143Sep 18 05:26 PM
Kauffman MichaelChief Executive OfficerSep 18Sale18.2610,000182,615512,143Sep 18 05:23 PM